Canine and human renal toxicity of inosine dialdehyde (NSC 118994).
A new antitumor agent, inosine dialdehyde, has shown minimal hematologic, but dose limiting, renal toxicity. The renal impairment is tubular necrosis due to reduction in renal blood by the drug. In addition, elevated serum calcium will return to normal within one week of drug administration. This effect is not secondary to urinary calcium excretion, but possibly an alteration of bone metabolism.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000447:Aldehydes / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity*; D002118:Calcium / Q000378:metabolism; D004285:Dogs; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007288:Inosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy; D011507:Proteinuria / Q000139:chemically induced; D012039:Regional Blood Flow / Q000187:drug effects
D000447:Aldehydes; D000970:Antineoplastic Agents; D007288:Inosine; D002118:Calcium